• PD 173074: Precision FGFR/VEGFR2 Inhibition in Cancer Resear

  2026-05-19

  PD 173074 stands out as a nanomolar-potent, highly selective FGFR1 and VEGFR2 inhibitor, unlocking robust workflows for dissecting angiogenesis and tumor progression. This guide details experimental setups, advanced troubleshooting, and actionable insights from recent epigenetic research, making PD-173074 from APExBIO the go-to tool for targeted pathway inhibition.

• BRCA1/BARD1–pre-rRNA Interaction Facilitates DNA Repair via

  2026-05-18

  This study demonstrates that the BRCA1/BARD1 complex directly recognizes pre-ribosomal RNA, enabling its recruitment to DNA double-strand breaks and promoting homologous recombination. The findings reveal a previously unappreciated RNA-dependent mechanism for DNA repair, with implications for understanding cancer susceptibility and refining transcriptional regulation assays.

• FXR-KLF11 Axis: CDCA Suppresses JAK2/STAT3 in AKI Models

  2026-05-18

  This study demonstrates that Chenodeoxycholic Acid (CDCA) confers renal protection in contrast-induced acute kidney injury (CI-AKI) by activating FXR, which upregulates KLF11 and suppresses the JAK2/STAT3 pathway. The findings establish the FXR-KLF11 axis as a mechanistic target for future interventions in AKI and nuclear receptor signaling research.

• AICAR and AMPK: Precision Modulation of Inflammatory Metabol

  2026-05-17

  Explore the advanced roles of AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) in inflammation inhibition via AMPK activation, with a focus on macrophage polarization and metabolic disease research. Gain unique insights grounded in cutting-edge literature and practical assay guidance.

• BMS 309403: Mechanistic Foundations for FABP4 Pathway Dissec

  2026-05-16

  Explore the mechanistic depth of BMS 309403, a potent FABP4 inhibitor, in dissecting lipid metabolism and inflammation. This article delivers advanced insights and practical guidance for optimizing atherosclerosis and metabolic disease research.

• MOG (35-55): Mechanisms, Models, and the Future of MS Resear

  2026-05-15

  Explore how the MOG (35-55) myelin oligodendrocyte glycoprotein peptide enables mechanistic insight and innovation in multiple sclerosis research. This article bridges foundational immunology, cutting-edge translational findings, and strategic guidance for researchers modeling neuroinflammation, with evidence-labeled protocol recommendations, a competitive landscape review, and visionary outlook on the next era of autoimmune encephalomyelitis research.

• AM251: Applied Workflows for CB1 Receptor Antagonist Researc

  2026-05-15

  AM251, a nanomolar-potency CB1 receptor antagonist from APExBIO, enables precise dissection of endocannabinoid signaling and metabolic regulation. This guide delivers actionable protocols and troubleshooting strategies, translating recent mechanistic insights into robust cannabinoid receptor research applications.

• Decitabine (5-Aza-2'-deoxycytidine): Protocols & Innovations

  2026-05-14

  Decitabine (5-Aza-2'-deoxycytidine) stands out as a powerful epigenetic modulator for both cancer and immune disease research, enabling robust tumor suppressor gene reactivation and immune tolerance restoration. This guide translates recent breakthroughs and benchmark protocols into actionable steps for hematopoietic and solid tumor workflows, with practical troubleshooting grounded in the latest literature.

• PGE2-Induced Schwann Cell Dedifferentiation Drives PDAC Nerv

  2026-05-14

  This study uncovers a mechanistic link between prostaglandin E2 (PGE2) signaling and Schwann cell dedifferentiation, facilitating perineural invasion (PNI) in pancreatic ductal adenocarcinoma (PDAC). By integrating transcriptomic profiling and functional assays, the authors identify the PTGES-PGE2 axis as a driver of tumor-nerve crosstalk and propose it as a promising therapeutic target.

• N4-Acetylcytidine: Precision Tools for RNA Modification Anal

  2026-05-13

  N4-Acetylcytidine empowers high-fidelity RNA epigenetics research, bridging structural insights with robust experimental workflows. APExBIO’s high-purity formulation enables reproducible assays, precise troubleshooting, and advanced enzyme characterization in post-transcriptional modification studies.

• Cy3 TSA Fluorescence System Kit: Amplifying Detection Precis

  2026-05-13

  The Cy3 TSA Fluorescence System Kit empowers researchers to visualize low-abundance biomolecules with high sensitivity, streamlining workflows in immunohistochemistry and in situ hybridization. Its robust tyramide signal amplification and compatibility with standard fluorescence microscopes make it indispensable for advanced molecular pathology and translational research.

• Targeting ATF4-Driven Enhancer Programs to Alleviate Liver F

  2026-05-12

  A recent study uncovers a non-canonical mechanism by which ATF4 promotes liver fibrosis through enhancer activation in hepatic stellate cells, independent of classical ER stress pathways. These findings suggest that selective inhibition of ATF4 translation—using compounds such as ISRIB (trans-isomer)—could offer new strategies for reversing fibrogenic processes in the liver.

• Digestive Fate of Withania somnifera Bioactives via LC-MS/MS

  2026-05-12

  This study systematically evaluated how key withanolide compounds from Withania somnifera (ashwagandha) leaf and root extracts are transformed during simulated digestion using advanced LC-MS/MS and metabolomic analysis. The findings highlight distinct stability and transformation patterns for major bioactives, refining our understanding of their potential bioavailability and informing preclinical model design.

• Nicotinamide Adenine Dinucleotide (NAD+): Beyond Metabolic S

  2026-05-11

  Explore how Nicotinamide Adenine Dinucleotide (NAD+) advances biochemical research beyond metabolic signaling, with a focus on its nuanced roles in cytoprotective autophagy and DNA damage response. This article offers new insights for assay development and experimental reproducibility.

• MLN2238: Proteasome β5 Subunit Inhibitor in Oncology Researc

  2026-05-11

  MLN2238 stands out as a next-generation proteasome β5 subunit inhibitor, enabling advanced workflows in apoptosis and drug-resistance research in hematologic malignancies. Its potent, reversible action and unique signaling impacts, including CREB modulation, position it as a transformative tool for both mechanistic and translational studies.

497 records 14/34 page Previous Next First page 上5页 1112131415 下5页 Last page